Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK127157-01)
- License Information
-
More Information
Article History
Accepted: 12 September 2022
First Online: 18 October 2022
Declarations
:
: Edward L. Barnes has served as a consultant for AbbVie, Eli Lilly, and Target RWE. Hans H. Herfarth has served as a consultant for Alivio, AMAG, Finch, Gilead, Lycera, Merck, Otsuka, Pfizer, PureTech, Seres and research support from Pfizer and Artizan Biosciences Kim Darlington has no conflicts of interest.
